Clinical Trial Update: A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

View source ↗

Summary

This clinical trial update describes real-world patterns of copanlisib use in people with relapsed or refractory Indolent Non-Hodgkin Lymphoma in Taiwan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Aliqopa (copanlisib)

Snippet

Sponsor: Bayer | Conditions: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | Status: COMPLETED